After a second investigation, the FDA announced tirzepatide will no longer be on the agency’s drug shortage list. Dates were announced for distribution of compounded forms for the drugs to end.

The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes/weight-loss med tirzepatide is over. Tirzepatide includes blockbuster ...

The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes ...